Published in N Engl J Med on November 21, 1991
BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax (1997) 9.69
What happened to the streptococci: overview of taxonomic and nomenclature changes. Clin Microbiol Rev (2002) 5.81
Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ (2009) 4.38
Guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. BMJ (1996) 3.79
Long term management of patients after splenectomy. BMJ (1993) 3.41
Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect Immun (1994) 3.01
Immune responses to recombinant pneumococcal PspA antigen delivered by live attenuated Salmonella enterica serovar typhimurium vaccine. Infect Immun (2002) 2.25
Pneumococcal diversity: considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA). Clin Microbiol Rev (1998) 2.06
Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis. Infect Immun (2001) 1.97
The pneumococcal problem. BMJ (1996) 1.69
Clinical effectiveness of pneumococcal vaccine. Meta-analysis. Can Fam Physician (1999) 1.60
Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur Respir J (2015) 1.55
Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A. J Exp Med (1994) 1.55
Should patients positive for HIV infection receive pneumococcal vaccine? BMJ (1995) 1.53
Serotype-specific mortality from invasive Streptococcus pneumoniae disease revisited. BMC Infect Dis (2004) 1.52
Older adults have a low capacity to opsonize pneumococci due to low IgM antibody response to pneumococcal vaccinations. Infect Immun (2010) 1.49
The effect of age on the B-cell repertoire. J Clin Immunol (2000) 1.47
Pandemic influenza and healthcare demand in the Netherlands: scenario analysis. Emerg Infect Dis (2003) 1.45
Extremely high incidence of macrolide and trimethoprim-sulfamethoxazole resistance among clinical isolates of Streptococcus pneumoniae in Taiwan. J Clin Microbiol (1999) 1.44
Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis (2012) 1.42
Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae. Clin Diagn Lab Immunol (2003) 1.38
Mouse antibody to phosphocholine can protect mice from infection with mouse-virulent human isolates of Streptococcus pneumoniae. Infect Immun (1992) 1.35
A live recombinant avirulent oral Salmonella vaccine expressing pneumococcal surface protein A induces protective responses against Streptococcus pneumoniae. Infect Immun (1998) 1.33
The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur J Epidemiol (2004) 1.32
Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines. Clin Microbiol Rev (2012) 1.31
Use of HL-60 cell line to measure opsonic capacity of pneumococcal antibodies. Clin Diagn Lab Immunol (2005) 1.28
The putative proteinase maturation protein A of Streptococcus pneumoniae is a conserved surface protein with potential to elicit protective immune responses. Infect Immun (2000) 1.28
Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination. Infect Immun (1999) 1.28
Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Fam Pract (2000) 1.26
Use of licensed vaccines for active immunization of the immunocompromised host. Clin Microbiol Rev (1998) 1.26
Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines. Clin Vaccine Immunol (2009) 1.25
Effects of ageing and gender on naturally acquired antibodies to pneumococcal capsular polysaccharides and virulence-associated proteins. Clin Vaccine Immunol (2008) 1.24
Somatic hypermutation and diverse immunoglobulin gene usage in the human antibody response to the capsular polysaccharide of Streptococcus pneumoniae Type 6B. Infect Immun (2004) 1.24
Isotypes and opsonophagocytosis of pneumococcus type 6B antibodies elicited in infants and adults by an experimental pneumococcus type 6B-tetanus toxoid vaccine. Infect Immun (1998) 1.24
Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults. Infect Immun (1997) 1.19
Intranasal immunization with heat-inactivated Streptococcus pneumoniae protects mice against systemic pneumococcal infection. Infect Immun (1999) 1.18
Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in nonresponders to the 23-valent pneumococcal vaccine. Infect Immun (2000) 1.18
Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax (2005) 1.17
Relative roles of genetic background and variation in PspA in the ability of antibodies to PspA to protect against capsular type 3 and 4 strains of Streptococcus pneumoniae. Infect Immun (2003) 1.15
Pneumococcal vaccination and revaccination of older adults. Clin Microbiol Rev (2003) 1.15
Candidate vaccine sequences to represent intra- and inter-clade HIV-1 variation. PLoS One (2009) 1.15
Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. J Infect Dis (2008) 1.14
The burden and outcomes associated with dehydration among US elderly, 1991. Am J Public Health (1994) 1.09
New vaccines for the prevention of pneumococcal infections. Emerg Infect Dis (1997) 1.07
Bacterial Infections Following Splenectomy for Malignant and Nonmalignant Hematologic Diseases. Mediterr J Hematol Infect Dis (2015) 1.07
Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency. Vaccine (2008) 1.06
PspK of Streptococcus pneumoniae increases adherence to epithelial cells and enhances nasopharyngeal colonization. Infect Immun (2012) 1.06
The immune response to pneumococcal polysaccharides 14 and 23F among elderly individuals consists predominantly of switched memory B cells. J Infect Dis (2013) 1.05
Racial disparities in receipt of influenza and pneumococcus vaccinations among US nursing-home residents. Am J Public Health (2010) 1.05
Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries. Eur J Clin Microbiol Infect Dis (2007) 1.05
Why the recent ACIP recommendations regarding conjugate pneumococcal vaccine in adults may be irrelevant. Hum Vaccin Immunother (2016) 1.03
Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections. Infect Immun (1999) 1.03
Pneumococcal bacteremia in Monroe County, New York. Am J Public Health (1992) 1.03
Pneumococcal vaccine--past, present, and future. N Engl J Med (1991) 1.03
Modulation of the lung inflammatory response to serotype 8 pneumococcal infection by a human immunoglobulin m monoclonal antibody to serotype 8 capsular polysaccharide. Infect Immun (2005) 1.02
The effect of age on the response to the pneumococcal polysaccharide vaccine. BMC Infect Dis (2010) 1.02
Genetic immunization with the region encoding the alpha-helical domain of PspA elicits protective immunity against Streptococcus pneumoniae. Infect Immun (2001) 1.01
Assignment of weight-based immunoglobulin G1 (IgG1) and IgG2 units in antipneumococcal reference serum lot 89-S(F) for pneumococcal polysaccharide serotypes 1, 4, 5, 7F, 9V, and 18C. Clin Diagn Lab Immunol (2005) 1.01
Disability and cognitive impairment are risk factors for pneumonia-related mortality in older adults. Public Health Rep (1993) 1.01
Routine immunization of adults in Canada: Review of the epidemiology of vaccine-preventable diseases and current recommendations for primary prevention. Can J Infect Dis Med Microbiol (2009) 1.01
A latex bead-based flow cytometric immunoassay capable of simultaneous typing of multiple pneumococcal serotypes (Multibead assay). Clin Diagn Lab Immunol (2000) 1.00
Intranasal immunization with pneumococcal conjugate vaccines with LT-K63, a nontoxic mutant of heat-Labile enterotoxin, as adjuvant rapidly induces protective immunity against lethal pneumococcal infections in neonatal mice. Infect Immun (2002) 0.99
Efficacy of opsonic and nonopsonic serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibodies against intranasal challenge with Streptococcus pneumoniae in mice. Infect Immun (2009) 0.99
Invasive pneumococcal infections among persons with and without underlying medical conditions: implications for prevention strategies. BMC Infect Dis (2008) 0.98
Trends in incidence of pneumococcal disease before introduction of conjugate vaccine: South West England, 1996-2005. Epidemiol Infect (2007) 0.97
Highly reduced protection against Streptococcus pneumoniae after deletion of a single heavy chain gene in mouse. Proc Natl Acad Sci U S A (2000) 0.97
Identification of D motif epitopes in Staphylococcus aureus fibronectin-binding protein for the production of antibody inhibitors of fibronectin binding. Infect Immun (1997) 0.97
Knowledge, attitudes, beliefs and behaviours of older adults about pneumococcal immunization, a Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) investigation. BMC Public Health (2014) 0.96
Comparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in adults 60 years old or older. Clin Vaccine Immunol (2009) 0.96
Staphylococcal Enterotoxin B-specific monoclonal antibody 20B1 successfully treats diverse Staphylococcus aureus infections. J Infect Dis (2013) 0.96
Synthesis of a conjugate vaccine composed of pneumococcus type 14 capsular polysaccharide bound to pertussis toxin. Infect Immun (1992) 0.95
The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004. BMC Infect Dis (2008) 0.94
Immune Responses to pneumococcal vaccines in children and adults: Rationale for age-specific vaccination. Aging Dis (2011) 0.93
Age-dependent preference in human antibody responses to Streptococcus pneumoniae polypeptide antigens. Clin Exp Immunol (2002) 0.93
A systems biology approach to the effect of aging, immunosenescence and vaccine response. Curr Opin Immunol (2014) 0.93
Pneumococcal conjugate vaccines for adults: reasons for optimism and for caution. Hum Vaccin Immunother (2014) 0.92
Influence of pneumococcal vaccines and respiratory syncytial virus on alveolar pneumonia, Israel. Emerg Infect Dis (2013) 0.91
Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds. Vaccine (2010) 0.90
Streptococcus pneumoniae. Thorax (1999) 0.90
Pneumococcal meningitis in the North East Thames Region UK: epidemiology and molecular analysis of isolates. Epidemiol Infect (1996) 0.90
Effect of influenza and pneumococcal vaccines in elderly persons in years of low influenza activity. Virol J (2008) 0.89
Pneumococcal serotype 19F conjugate vaccine induces cross-protective immunity to serotype 19A in a murine pneumococcal pneumonia model. Infect Immun (2003) 0.89
Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine. Infect Immun (2010) 0.89
Is there any connection between a second pneumonia shot and hospitalization among Medicare beneficiaries? Public Health Rep (1996) 0.88
How advances in immunology provide insight into improving vaccine efficacy. Vaccine (2014) 0.88
The Streptococcus pneumoniae capsule is required for full virulence in pneumococcal endophthalmitis. Invest Ophthalmol Vis Sci (2011) 0.87
Inhaled delivery of 23-valent pneumococcal polysaccharide vaccine does not result in enhanced pulmonary mucosal immunoglobulin responses. Vaccine (2008) 0.87
Anti-endotoxin vaccines: back to the future. Virulence (2013) 0.86
The 23-valent pneumococcal polysaccharide vaccine. Part II. A cost-effectiveness analysis for invasive disease in the elderly in England and Wales. Eur J Epidemiol (2004) 0.86
Serotypes of Streptococcus pneumoniae blood culture isolates from adults in Franklin County, Ohio. J Clin Microbiol (1994) 0.86
Defective IgG2 response to Pneumovax in HIV seropositive patients. Genitourin Med (1993) 0.85
Attributable healthcare utilization and cost of pneumonia due to drug-resistant streptococcus pneumonia: a cost analysis. Antimicrob Resist Infect Control (2014) 0.85
Cellular basis of decreased immune responses to pneumococcal vaccines in aged mice. Infect Immun (1996) 0.85
Deletion of arcD in Streptococcus pneumoniae D39 impairs its capsule and attenuates virulence. Infect Immun (2013) 0.84
A Review of Pneumococcal Vaccines: Current Polysaccharide Vaccine Recommendations and Future Protein Antigens. J Pediatr Pharmacol Ther (2016) 0.83
Factors influencing early and late mortality in adults with invasive pneumococcal disease in Calgary, Canada: a prospective surveillance study. PLoS One (2013) 0.83
Antibody responses to pneumococcal and hemophilus vaccinations in splenectomized patients with hematological malignancies or trauma. Wien Klin Wochenschr (2007) 0.83
Social mixing with other children during infancy enhances antibody response to a pneumococcal conjugate vaccine in early childhood. Clin Vaccine Immunol (2007) 0.83
A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA). Vaccine (2013) 0.83
Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J (2000) 11.94
Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ (1999) 8.93
Emergence of multiply resistant pneumococci. N Engl J Med (1978) 8.32
Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis (1983) 6.15
Typhoid fever in children aged less than 5 years. Lancet (1999) 6.00
Phase variation in pneumococcal opacity: relationship between colonial morphology and nasopharyngeal colonization. Infect Immun (1994) 4.90
Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet (1997) 4.56
The quellung reaction, a neglected microbiologic technique. Mt Sinai J Med (1977) 3.78
Trial of calcium to prevent preeclampsia. N Engl J Med (1997) 3.69
A controlled trial of antimicrobial prophylaxis for Lyme disease after deer-tick bites. N Engl J Med (1992) 3.65
Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physicians (1976) 3.49
Some aspects of the pneumococcal carrier state. J Antimicrob Chemother (1986) 3.25
Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention. Rev Infect Dis (1981) 2.93
Pathogenesis of pneumococcal infection. N Engl J Med (1995) 2.87
Field trial of oral cholera vaccines in Bangladesh. Lancet (1986) 2.85
Green fluorescent protein functions as a reporter for protein localization in Escherichia coli. J Bacteriol (2000) 2.70
A radioimmunoassay for immunologic phenomena in pneumococcal disease and for the antibody response to pneumococcal vaccines. I. Method for the radioimmunoassay of anticapsular antibodies and comparison with other techniques. J Immunol Methods (1980) 2.65
The BCG controversy. A methodological and statistical reappraisal. JAMA (1983) 2.60
The burden of cholera in the slums of Kolkata, India: data from a prospective, community based study. Arch Dis Child (2005) 2.59
Cholera in India: an analysis of reports, 1997-2006. Bull World Health Organ (2010) 2.52
Worsening of quality of life after epilepsy surgery: effect of seizures and memory decline. Neurology (2007) 2.48
Qualitative differences in the behavior of pneumoncoccal deoxyribonucleic acids transforming to the same capsular type. J Bacteriol (1967) 2.46
Maxwell Finland Lecture. Random gleanings from a life with the pneumococcus. J Infect Dis (1975) 2.38
An educational intervention for altering water-sanitation behaviors to reduce childhood diarrhea in urban Bangladesh. II. A randomized trial to assess the impact of the intervention on hygienic behaviors and rates of diarrhea. Am J Epidemiol (1987) 2.38
Treatment and vaccination strategies to control cholera in sub-Saharan refugee settings: a cost-effectiveness analysis. JAMA (1998) 2.37
Streptococcus pneumoniae type 16A, a hitherto undescribed pneumococcal type. J Clin Microbiol (1985) 2.34
Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: a multicenter prospective study. JAMA (1999) 2.34
A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern Med (1984) 2.27
Twenty-four-hour recall, knowledge-attitude-practice questionnaires, and direct observations of sanitary practices: a comparative study. Bull World Health Organ (1987) 2.24
Importance of carbon dioxide in the isolation of pneumococci. J Bacteriol (1966) 2.21
Serum cotinine concentration and self-reported smoking during pregnancy. Am J Epidemiol (1998) 2.15
Spread of Streptococcus pneumoniae in families. II. Relation of transfer of S. pneumoniae to incidence of colds and serum antibody. J Infect Dis (1975) 2.05
Capsular polysaccharide types of group B streptococcal isolates from neonates with early-onset systemic infection. J Infect Dis (1998) 2.01
Impact of measles vaccination on childhood mortality in rural Bangladesh. Bull World Health Organ (1990) 1.95
Developing improved observational methods for evaluating therapeutic effectiveness. Am J Med (1990) 1.93
Predicting long-term seizure outcome after resective epilepsy surgery: the multicenter study. Neurology (2005) 1.93
High seroprevalence of hepatitis A, B, C, and E viruses in residents in an Egyptian village in The Nile Delta: a pilot study. Am J Trop Med Hyg (1996) 1.86
An outbreak of typhoid fever, Xing-An County, People's Republic of China, 1999: estimation of the field effectiveness of Vi polysaccharide typhoid vaccine. J Infect Dis (2001) 1.86
The relationship between abnormal glucose tolerance and hypertensive disorders of pregnancy in healthy nulliparous women. Calcium for Preeclampsia Prevention (CPEP) Study Group. Am J Obstet Gynecol (1998) 1.81
Initial outcomes in the Multicenter Study of Epilepsy Surgery. Neurology (2003) 1.79
Prevalence and predictors of the prone sleep position among inner-city infants. JAMA (1998) 1.74
Predictors of epilepsy surgery outcome: a meta-analysis. Epilepsy Res (2004) 1.71
Pneumococcal infection and pneumococcal vaccine. N Engl J Med (1977) 1.69
How long do new-onset seizures in children last? Ann Neurol (2001) 1.67
Insulin improves survival in a canine model of acute beta-blocker toxicity. Ann Emerg Med (1997) 1.65
Capsulation of pneumococcus with soluble C-like (Cs) polysaccharide. I. Biological and genetic properties of Cs pneumococcal strains. J Exp Med (1968) 1.65
The risk of seizure recurrence after a first unprovoked afebrile seizure in childhood: an extended follow-up. Pediatrics (1996) 1.65
Pneumococcal vaccine. Efficacy and associated cost savings. JAMA (1990) 1.64
Discontinuing antiepileptic drugs in children with epilepsy: a prospective study. Ann Neurol (1994) 1.63
Predictors of multiple seizures in a cohort of children prospectively followed from the time of their first unprovoked seizure. Ann Neurol (2000) 1.56
Novel penicillin-resistant clones of Streptococcus pneumoniae in the Czech Republic and in Slovakia. Microb Drug Resist (1995) 1.56
The bacterial flora of the respiratory tract. Some knowns and unknowns. Yale J Biol Med (1968) 1.56
Prospects for the prevention of bacterial meningitis with polysaccharide vaccines. Bull World Health Organ (1978) 1.52
Pneumococcal vaccine: development and prospects. Am J Med (1979) 1.51
Marital status and psychiatric disorders among blacks and whites. J Health Soc Behav (1992) 1.50
B subunit-whole cell and whole cell-only oral vaccines against cholera: studies on reactogenicity and immunogenicity. J Infect Dis (1987) 1.47
Breast feeding as a determinant of severity in shigellosis. Evidence for protection throughout the first three years of life in Bangladeshi children. Am J Epidemiol (1986) 1.46
Pathogenicity and convalescent excretion of Campylobacter in rural Egyptian children. Am J Epidemiol (2001) 1.45
Resolving the pneumococcal vaccine controversy: are there alternatives to randomized clinical trials? Rev Infect Dis (1984) 1.44
Ultra-low wear rates for rigid-on-rigid bearings in total hip replacements. Proc Inst Mech Eng H (2000) 1.42
Changes in depression and anxiety after resective surgery for epilepsy. Neurology (2005) 1.40
Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up. Vaccine (1996) 1.39
Blink rate: a possible measure of fatigue. Hum Factors (1994) 1.38
STUDIES ON THE ANTIBACTERIAL ACTION OF THE SULFONAMIDE DRUGS : II. THE POSSIBLE RELATION OF DRUG ACTIVITY TO SUBSTANCES OTHER THANp-AMINOBENZOIC ACID. J Exp Med (1942) 1.37
Are children born to young mothers at increased risk of maltreatment? Pediatrics (1993) 1.37
The bacteriology of pneumococcal otitis media. Johns Hopkins Med J (1977) 1.36
Pneumococcus: the first one hundred years. Rev Infect Dis (1981) 1.36
Pneumococcal pneumonia. Diagnostic, epidemiologic, therapeutic and prophylactic considerations. Chest (1986) 1.36
Phenotypic diversity of enterotoxigenic Escherichia coli strains from a community-based study of pediatric diarrhea in periurban Egypt. J Clin Microbiol (1999) 1.35
Some biological properties of Pneumococcus type 37 and the chemistry of its capsular polysaccharide. J Exp Med (1970) 1.34
Type variation of strains of Streptococcus pneumoniae in capsular serogroup 15. J Infect Dis (1983) 1.33
From the center for disease control. Epidemiology of pneumococcal serotypes in the United States, 1978--1979. J Infect Dis (1980) 1.32
Prevention of pneumococcal infection by immunization with capsular polysaccharides of Streptococcus pneumoniae: current status of polyvalent vaccines. J Infect Dis (1977) 1.31
Immune response to acute otitis media in children. I. Serotypes isolated and serum and middle ear fluid antibody in pneumococcal otitis media. Infect Immun (1974) 1.30
Maternal serum paraxanthine, a caffeine metabolite, and the risk of spontaneous abortion. N Engl J Med (1999) 1.29
Safety and immunogenicity of an oral, killed enterotoxigenic Escherichia coli-cholera toxin B subunit vaccine in Egyptian adults. J Infect Dis (1998) 1.26
Serotypes responsible for invasive Streptococcus pneumoniae infections among children in Connecticut. J Infect Dis (1994) 1.25
Stochastic resonance at the single-cell level. Nature (1997) 1.23
Reactivities of serotyping monoclonal antibodies with culture-adapted human rotaviruses. J Clin Microbiol (1991) 1.22
Epidemiology of rotavirus diarrhea in Egyptian children and implications for disease control. Am J Epidemiol (1999) 1.22
Ultrasonic evaluation of lymphocele formation after staging lymphadenectomy for prostatic carcinoma. Radiology (1981) 1.21
Epidemiology of enterotoxigenic Escherichia coli diarrhea in a pediatric cohort in a periurban area of lower Egypt. J Infect Dis (1999) 1.21
Need for agreement on a single pneumococcal vaccine formulation. Lancet (1980) 1.21
Incidence of Haemophilus influenzae type b and other invasive diseases in South Korean children. Vaccine (2004) 1.20
Evidence for natural reassortants of human rotaviruses belonging to different genogroups. J Virol (1990) 1.20
Oral, inactivated, whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine: results of the initial evaluation in children. PRIDE Study Group. J Infect Dis (1999) 1.20
Changing spectrum of infective endocarditis in children. Analysis of 26 cases, 1970-1979. Am J Dis Child (1984) 1.20
Safety and immunogenicity of the oral, whole cell/recombinant B subunit cholera vaccine in North American volunteers. J Infect Dis (1993) 1.20
Prevalence and predictors of immunization among inner-city infants: a birth cohort study. Pediatrics (2001) 1.19
Distribution of epilepsy syndromes in a cohort of children prospectively monitored from the time of their first unprovoked seizure. Epilepsia (1999) 1.18
Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover. Calcif Tissue Int (1994) 1.18
Astrovirus diarrhea in Egyptian children. J Infect Dis (2000) 1.17
Current status of bacterial pneumonia with special reference to pneumococcal infection. J Clin Pathol Suppl Coll Pathol (1968) 1.17
The assessment of pneumococcal vaccine. N Engl J Med (1980) 1.17
Risk of seizure recurrence following a first unprovoked seizure in childhood: a prospective study. Pediatrics (1990) 1.17
Why have group A streptococci remained susceptible to penicillin? Report on a symposium. Clin Infect Dis (1998) 1.16
Restricted driving for people with epilepsy. Neurology (1999) 1.15
A voluntary serosurvey and behavioral risk assessment for human immunodeficiency virus infection among college students. Sex Transm Dis (1992) 1.15
Screening for lead poisoning in an urban pediatric clinic using samples obtained by fingerstick. Pediatrics (1994) 1.15